Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Cancer Prev Res (Phila). 2022 Apr 1;15(4):255–264. doi: 10.1158/1940-6207.CAPR-21-0467

Table 5:

Hazard ratios for the association of predicted REE (Mifflin) with risk of incident, invasive breast cancer in postmenopausal women, overall and by breast cancer subtype

Quintiles


1 2 3 4 5 P-trend


Invasive breast cancer
 Cases (N) 1,497 1,753 1,940 2,043 2,093
 Age-adjusted HR (95% CI) 1.00 1.08 (1.00–1.15) 1.21 (1.13–1.29) 1.34 (1.25–1.43) 1.54 (1.43–1.65) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.11 (1.03–1.19) 1.26 (1.17–1.35) 1.42 (1.32–1.53) 1.68 (1.56–1.80) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.16 (0.99–1.14) 1.16 (1.08–1.25) 1.26 (1.16–1.36) 1.34 (1.21–1.48) <0.001
ER+/PR+ breast cancer
 Cases (N) 930 1,127 1,257 1,354 1,384
 Age-adjusted HR (95% CI) 1.00 1.12 (1.03–1.22) 1.28 (1.17–1.39) 1.45 (1.33–1.58) 1.69 (1.55–1.84) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.16 (1.06–1.27) 1.35 (1.24–1.47) 1.58 (1.44–1.72) 1.90 (1.73–2.08) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.10 (1.01–1.21) 1.22 (1.11–1.34) 1.34 (1.21–1.48) 1.41 (1.24–1.60) <0.001
ER+/PR- breast cancer
 Cases (N) 195 269 255 225 226
 Age-adjusted HR (95% CI) 1.00 1.30 (1.08–1.56) 1.26 (1.04–1.52) 1.17 (0.96–1.43) 1.34 (1.09–1.63) 0.053
 Multivariable-adjusted* HR (95% CI) 1.00 1.32 (1.10–1.60) 1.28 (1.06–1.56) 1.22 (0.99–1.49) 1.40 (1.14–1.73) 0.023
 Multivariable-adjusted** HR (95% CI) 1.00 1.34 (1.10–1.62) 1.30 (1.06–1.60) 1.25 (0.99–1.57) 1.46 (1.09–1.96) <0.001
ER−/PR− breast cancer
 Cases (N) 193 197 241 236 246
 Age-adjusted HR (95% CI) 1.00 0.90 (0.74–1.10) 1.09 (0.89–1.32) 1.09 (0.90–1.33) 1.24 (1.02–1.52) 0.004
 Multivariable-adjusted* HR (95% CI) 1.00 0.91 (0.74–1.11) 1.08 (0.89–1.32) 1.09 (0.89–1.33) 1.19 (0.96–1.46) 0.025
 Multivariable-adjusted** HR (95% CI) 1.00 0.89 (0.72–1.09) 1.04 (0.84–1.28) 1.02 (0.81–1.28) 1.05 (0.78–1.40) 0.476
Localised
 Cases (N) 1,127 1,349 1,451 1,563 1,520
 Age-adjusted HR (95% CI) 1.00 1.10 (1.02–1.20) 1.21 (1.12–1.31) 1.38 (1.27–1.49) 1.52 (1.40–1.65) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.14 (1.06–1.24) 1.27 (1.17–1.38) 1.48 (1.37–1.61) 1.69 (1.55–1.84) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.11 (1.02–1.20) 1.19 (1.10–1.30) 1.34 (1.22–1.47) 1.40 (1.24–1.57) <0.001
Advanced
 Cases (N) 322 363 436 439 504
 Age-adjusted HR (95% CI) 1.00 1.01 (0.90–1.18) 1.21 (1.04–1.40) 1.26 (1.09–1.46) 1.60 (1.38–1.85) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.03 (0.88–1.19) 1.23 (1.06–1.43) 1.30 (1.12–1.51) 1.64 (1.41–1.92) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 0.97 (0.84–1.14) 1.12 (0.96–1.31) 1.11 (0.94–1.32) 1.24 (1.001–1.53) 0.027
Low grade
 Cases (N) 405 477 505 532 493
 Age-adjusted HR (95% CI) 1.00 1.07 (0.93–1.22) 1.14 (0.99–1.30) 1.26 (1.10–1.44) 1.32 (1.15–1.52) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.11 (0.97–1.27) 1.21 (1.06–1.39) 1.39 (1.21–1.60) 1.54 (1.33–1.78) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.08 (0.94–1.24) 1.14 (0.99–1.32) 1.27 (1.08–1.48) 1.30 (1.06–1.59) 0.002
Intermediate grade
 Cases (N) 647 732 813 867 884
 Age-adjusted HR (95% CI) 1.00 1.04 (0.93–1.15) 1.17 (1.05–1.30) 1.31 (1.18–1.46) 1.51 (1.36–1.68) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.07 (0.96–1.19) 1.23 (1.11–1.37) 1.42 (1.27–1.58) 1.69 (1.51–1.89) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.03 (0.92–1.15) 1.14 (1.02–1.27) 1.25 (1.11–1.41) 1.35 (1.15–1.57) <0.001
High grade
 Cases (N) 305 366 427 460 510
 Age-adjusted HR (95% CI) 1.00 1.09 (0.94–1.28) 1.28 (1.11–1.49) 1.44 (1.24–1.68) 1.78 (1.53–2.07) <0.001
 Multivariable-adjusted* HR (95% CI) 1.00 1.11 (0.95–1.30) 1.30 (1.12–1.51) 1.47 (1.26–1.71) 1.78 (1.53–2.09) <0.001
 Multivariable-adjusted** HR (95% CI) 1.00 1.07 (0.91–1.25 1.21 (1.03–1.32) 1.30 (1.10–1.55) 1.43 (1.16–1.77) <0.001

Abbreviations: REE= resting energy expenditure, HR= hazard ratio; CI= confidence interval; ER = estrogen receptor, PR= progesterone receptor

*

Also adjusted for education, physical activity, smoking status, alcohol consumption, randomization group/study arm, unopposed estrogen therapy ever use, combined estrogen and progesterone therapy use ever, breastfed ever, age at menopause, oral contraceptive, healthy eating index 2015, age at menarche and age at first full‐term pregnancy, race and ethnicity

**

Also adjusted for BMI